Roth Capital downgraded shares of OHR Pharmaceutical (NASDAQ:OHRP) from a buy rating to a neutral rating in a research report released on Friday, January 5th, MarketBeat reports. The firm currently has $7.00 target price on the biotechnology company’s stock.
Several other research analysts have also recently weighed in on the company. ValuEngine raised OHR Pharmaceutical from a strong sell rating to a sell rating in a research note on Friday, December 1st. Zacks Investment Research cut OHR Pharmaceutical from a buy rating to a hold rating in a research note on Thursday, October 26th.
Shares of OHR Pharmaceutical (NASDAQ OHRP) remained flat at $$0.33 on Friday. The company’s stock had a trading volume of 1,548,210 shares, compared to its average volume of 4,120,000. The stock has a market capitalization of $18.53, a P/E ratio of -0.56 and a beta of 0.48. OHR Pharmaceutical has a 12 month low of $0.31 and a 12 month high of $2.18.
OHR Pharmaceutical (NASDAQ:OHRP) last released its quarterly earnings results on Friday, December 15th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.08).
Hedge funds and other institutional investors have recently made changes to their positions in the company. Garrison Bradford & Associates Inc. lifted its holdings in shares of OHR Pharmaceutical by 482.4% during the third quarter. Garrison Bradford & Associates Inc. now owns 497,415 shares of the biotechnology company’s stock valued at $358,000 after purchasing an additional 412,000 shares during the last quarter. Wedbush Securities Inc. purchased a new stake in shares of OHR Pharmaceutical during the third quarter valued at $311,000. Finally, Vanguard Group Inc. lifted its stake in OHR Pharmaceutical by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock worth $520,000 after acquiring an additional 5,481 shares in the last quarter. 8.25% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Roth Capital Downgrades OHR Pharmaceutical (OHRP) to Neutral” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/28/ohr-pharmaceuticals-ohrp-lowered-to-neutral-at-roth-capital.html.
About OHR Pharmaceutical
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.